Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Manufacturing Regulatory Updates In Brief: Elemental Impurities, Class 3 Biowaivers, FDA Salt Policy

Executive Summary

Manufacturing US regulatory updates for December 2017: Elemental impurities requirements begin Jan. 1, final guidance confirms BCS Class 3 biowaivers option, and FDA MAPP implements USP salt policy.

You may also be interested in...



ANDA Approvals May Be Hindered By New Elemental Impurities Requirements

US FDA's generic approval total in January was dramatically lower than recent monthly tallies, raising questions about impact of requirements that took effect at beginning of the year.

ANDA Approvals May Be Hindered By New Elemental Impurities Requirements

US FDA's generic approval total in January was dramatically lower than recent monthly tallies, raising questions about impact of requirements that took effect at beginning of the year.

Risk Assessments Of New Drug Elemental Impurities Get Mixed Reviews From Regulators

ICH Q3D went into effect in June 2016 for new drugs, but so far doesn't seem to have completely resolved worries about the presence of elemental impurities in drug products.

Related Content

Topics

UsernamePublicRestriction

Register

PS122211

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel